西格列汀对2型糖尿病患者血管内皮依赖性舒张功能的影响

【摘要】 目的 观察西格列汀对 2 型糖尿病患者血管内皮依赖性舒张功能（FMD）的影响。 方法 将 90 例联合应用多种降糖药物血糖仍控制不佳的 2 型糖尿病患者随机分为西格列汀组和对照组各 45 例。 对照组维持原降糖方案， 西格列汀组在原方案基础上加用西格列汀 100 mg/d， 治疗 12周。 观察 2组患者治疗前后 FMD、空腹血糖（FPG）、餐后 2 h 血糖（2 hPPG）、糖化血红蛋白（HbA1c）、空腹 C 肽（C-P） 及餐后 2 hC 肽（2 h C-P） 变化。 结果 治疗前 2 组FMD、FPG、2 hPPG、HbA1c、C-P、2 h C-P比较差异无统计学意义。 治疗 12周后与对照组比较， 西格列汀组 FMD、空腹C 肽、餐后 2 h-C 肽、FPG、2 hPPG、HbA1c 均有降低（P＜ 0.05）。 治疗过程中西格列汀组出现低血糖反应 1 例， 无严重不良反应发生。 结论 西格列汀能改善 2型糖尿病患者血管内皮依赖性舒张功能。 对血糖控制不佳的 2型糖尿病患者能安全有效控制血糖， 且患者耐受性好。

Effects of Sitagliptin on Vascular Endothelial Function in Type 2 Diabetes

[Abstract] Objective To investigate the effects of Sitagliptin on vascular endothelial function in in Type 2 Diabetes. Methods 45 patients with Type 2 Diabetes Controlled With combination therapy with insulin or other oral hypoglycaemic agents were run-in to the addition of once-daily sitagliptin 100 mg over a 12-week study period. Before and after the treatment o f 16 weeks, The flow-mediated dilation (FMD), fasting plasma glucose(FPG), 2-h postmeal glucose (2hPG), C-peptide, HbAlc and Lipids were measured. Results The FMD was significantly increased after treatment (p < 0.001). At 12 weeks, the addition of sitagliptin significantly reduced HbA1c(p < 0.05), fasting plasma glucose and 2-h postmeal glucose(p < 0.001). The plasma C-peptide levels significantly increased(p < 0.05), Whereas The change in BMI and lipids were not significantly different(p＞0.05).There was two hypoglycaemic events during the treatment. There was no severe adverse. Conclusion sitagliptin can improve the endothelial function in Type 2 Diabetes.For patients with Type 2 Diabetes Inadequately Controlled With combination therapy with insulin or other oral hypoglycaemic agents, sitagliptin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes.Without the significant change in body weight.